Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021

A new study establishing accurate reference intervals for pregnant patients was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo and could help resolve persistent challenges in lab testing for women. More...



Researchers from BC Children’s and Women’s Hospital (Vancouver, Canada) have established accurate reference intervals for coagulation tests commonly ordered for peripartum patients (i.e., patients who are about to or have just given birth).

A key obstacle in women’s health is the lack of standardized reference intervals for patients who are pregnant or have just given birth. To correctly interpret lab test results, providers must evaluate results within the context of reference intervals, which are the range of normal test values that indicate a person is healthy. However, pregnancy affects proteins and other biomarkers measured by common lab tests. This means that using existing reference intervals for pregnant patients can lead to incorrect interpretation of their lab results, which in turn can lead to subpar maternity care.

The research team collected and analyzed blood samples from an ethnically diverse group of more than 400 healthy patients with singleton pregnancies before and after delivery. The team then calculated reference intervals using eligible test results from 196 of the participants. The new intervals revealed that peripartum patients have different levels of fibrinogen, von Willebrand factor, and other proteins involved in bleeding and clotting compared with non-pregnant adults.

“Lab testing in pregnant women should be compared to reference intervals specific for pregnancy,” said Ann Tran, MD, from the BC Children’s and Women’s Hospital. “If a lab does not have pregnancy-specific reference intervals, then any out-of-range lab values should be interpreted cautiously and with knowledge of how pregnancy itself can change lab values.”

Related Links:
BC Children’s and Women’s Hospital


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: AI blood-based cell-free DNA analyses detect early liver fibrosis and other diseases (Photo courtesy of Shutterstock)

AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals

Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.